Getting big returns from financial portfolios, whether through stocks, bonds, ETFs, other securities, or a combination of all, is an investor's dream. But when you're an income investor, your primary ...

Karen Hale, who joined Novartis in 2021 as chief legal officer, will take on the new chief legal and compliance officer role.

Novartis AG's plan to sell its 70.68% stake in Novartis India faces challenges due to market volatility impacting valuation.

After much delay, Novartis has finally won a key FDA go-ahead for Pluvicto, opening up the radioligand therapy to a much ...

Pluvicto can now be used before chemotherapy to treat a kind of metastatic prostate cancer, tripling the number of patients ...

Novartis' Fabhalta has become the first treatment approved by the FDA for the ultra-rare kidney disease C3G. But analysts ...

Novartis radioligand therapy, Pluvicto gets US FDA approval for earlier use before chemotherapy in PSMA-positive mCRPC: Basel Monday, March 31, 2025, 13:00 Hrs [IST] Novartis anno ...

To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter. On Wednesday, Novartis gave a more ...

Basel: Novartis has announced the appointment of Karen Hale to the expanded role of Chief Legal and Compliance Officer for ...

Basel, March 20, 2025 – Novartis today announced that oral Fabhalta ® (iptacopan) has received U.S. Food and Drug Administration (FDA) approval for the treatment of adults with C3 glomerulopathy (C3G) ...